{{Rsnum
|rsid=3211371
|Gene=CYP2B6
|Chromosome=19
|position=41016810
|Orientation=plus
|ReferenceAllele=C
|MissenseAllele=T
|GMAF=0.05051
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=CYP2B6
}}[[rs3211371]], also known as 1459C>T, is a SNP encoding the CYP2B6*5 allele of the [[CYP2B6]] gene.

{{PharmGKB
|RSID=rs3211371
|Name_s=CYP2B6:1459C>T; CYP2B6:Arg487Cys; part of CYP2B6*1C, CYP2B6*5, CYP2B6*7
|Gene_s=CYP2B6, CYP2A7P1
|Feature=Exon/NonSyn, Intron
|Evidence=Web Resource:http://www.pharmgkb.org/search/annotatedGene/cyp2b6/variant.jsp
|Annotation=CYP2B6:1459C>T has been reported to reduce CYP2B6 protein expression in human liver and brain. Impact on drug response is somewhat contradictory, see VIP annotation for details.
|Drugs=bupropion; efavirenz; mephenytoin; nevirapine; nicotine
|Drug Classes=
|Diseases=
|Curation Level=In-Depth
|PharmGKB Accession ID=PA164891495
}}

{{PharmGKB
|RSID=rs3211371
|Name_s=*5, 1459C>T, Arg487Cys
|Gene_s=CYP2B6, CYP2A7P1
|Feature=Exon/NonSyn, Intron
|Evidence=Web Resource:http://www.cypalleles.ki.se/cyp2b6.htm
|Annotation=The 1459C>T variant is the determining SNP of the *5 allele and a component SNP of the *7 allele. Livers from individuals with the 1459C>T variant had 8 fold lower activity as determined by demethylation of the drug mephenytoin.
|Drugs=mephenytoin
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA161659484
}}

{{PMID Auto
|PMID=21886015
|Title=Cytochrome P450 CYP2B6 genotypes and haplotypes in a Colombian population: identification of novel variant CYP2B6 alleles
}}
{{PMID Auto
|PMID=19076156
|Title=Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.
|OA=1
}}

{{PMID Auto
|PMID=19154420
|Title=The impact of cytokines on the expression of drug transporters, cytochrome P450 enzymes and chemokine receptors in human PBMC.
|OA=1
}}

{{PMID Auto
|PMID=20459744
|Title=Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study.
|OA=1
}}

{{PMID Auto
|PMID=21172166
|Title=Pharmacogenetics of antidepressant response.
|OA=1
}}

{{GET Evidence
|gene=CYP2B6
|aa_change=Arg487Cys
|aa_change_short=R487C
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs3211371
|overall_frequency_n=944
|overall_frequency_d=10758
|overall_frequency=0.0877487
|n_genomes=5
|n_genomes_annotated=0
|n_haplomes=5
|n_articles=0
|n_articles_annotated=0
|in_pharmgkb=Y
|pph2_score=0.005
|nblosum100=8
|autoscore=1
|webscore=N
}}

{{PMID Auto
|PMID=23249875
|Title=Contribution of CYP2B6 alleles in explaining extreme (S)-methadone plasma levels:  a CYP2B6 gene resequencing study
}}

{{PMID Auto
|PMID=24260284
|Title=CYP2B6 Non-Coding Variation Associated with Smoking Cessation Is Also Associated with Differences in Allelic Expression, Splicing, and Nicotine Metabolism Independent of Common Amino-Acid Changes
|OA=1
}}

{{PMID Auto
|PMID=23133420
|Title=Pharmacogenomic Diversity among Brazilians: Influence of Ancestry, Self-Reported Color, and Geographical Origin.
|OA=1
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}